文献速递前列腺增生与排尿功能障碍

神经生长因子水平与前列腺增生患者膀胱过度活动症状及经尿道前列腺电切术后长期疗效相关

Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia.
PubMed 文献 · J Urol · 2018-04-07

前瞻性纳入北京大学人民医院178例良性前列腺增生患者,术前用酶联免疫吸附法测定尿神经生长因子/肌酐水平并评估症状与尿动力学,术后1年复评。尿神经生长因子/肌酐与膀胱过度活动症状分级相关,术后1年显著下降,且基线及术后水平与长期疗效相关。

要点

  • 尿神经生长因子/肌酐水平随膀胱过度活动症状加重而升高
  • 经尿道前列腺电切术后1年尿神经生长因子/肌酐及症状评分均显著下降
  • 基线及术后1年尿神经生长因子/肌酐较高者长期疗效偏差

核心结论

  • 神经生长因子与良性前列腺增生患者的膀胱过度活动症状相关,也与膀胱出口梗阻伴膀胱过度活动症状患者经尿道前列腺电切术后长期疗效的评估相关。

研究设计与样本

  • 前瞻性研究,纳入北京大学人民医院2011年1月至2013年1月178例良性前列腺增生患者。
  • 术前采用商业酶联免疫吸附试剂盒测定尿神经生长因子水平,并测定前列腺体积、I-PSS、生活质量、OABSS、超声估计残余尿及尿动力学。
  • 经尿道前列腺电切术后1年复评尿神经生长因子水平、I-PSS与OABSS。

主要发现

  • 中度与重度下尿路症状患者尿神经生长因子/肌酐水平分别为10.513±4.255与12.334±4.048 pg/μmol,p=0.002。
  • 膀胱出口梗阻III/IV级与V/VI级患者尿神经生长因子/肌酐分别为11.285±4.069与11.781±4.437 pg/μmol,p=0.354,无显著差异。
  • 无膀胱过度活动及轻度、中度、重度膀胱过度活动患者尿神经生长因子/肌酐分别为8.132±3.489、10.128±3.817、13.232±3.290与14.029±3.820 pg/μmol,p<0.001。
  • 术后1年尿神经生长因子/肌酐较基线降至8.978±4.022 pg/μmol(p<0.001),I-PSS与OABSS分别为10.2±5.4与4.3±3.7(各p<0.001)。
  • 疗效良好组与一般/差组的基线尿神经生长因子/肌酐分别为11.015±4.298与12.319±4.017 pg/μmol(p=0.045),术后1年分别为7.850±3.419与10.847±4.267 pg/μmol(p<0.001),术后变化分别为3.165±4.863与1.472±4.928 pg/μmol(p=0.031)。

临床怎么用

  • 对良性前列腺增生合并膀胱过度活动症状患者,可参考尿神经生长因子/肌酐水平评估症状严重程度及预判经尿道前列腺电切术后长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated changes in urinary nerve growth factor in patients with benign prostatic hyperplasia after transurethral prostate resection. We also assessed the association between nerve growth factor and changes of overactive bladder symptoms and long-term treatment outcomes after surgery. MATERIALS AND METHODS: This was a prospective study of 178 patients at Peking University People's Hospital with benign prostatic hyperplasia between January 2011 and January 2013. Urinary nerve growth factor levels were determined preoperatively using a commercial enzyme-linked immunosorbent assay kit. We also determined prostate volume, I-PSS (International Prostate Symptom Score), quality of life, OABSS (Overactive Bladder Symptom Score), ultrasound estimated post-void residual urine and urodynamics before surgery. Urinary nerve growth factor levels, I-PSS and OABSS were assessed again 1 year after transurethral prostate resection. RESULTS: Urinary nerve growth factor/creatinine levels differed between patients with moderate and severe lower urinary tract symptoms (mean ± SD 10.513 ± 4.255 vs 12.334 ± 4.048 pg/μmol, p = 0.002). There was no significant difference between patients with grades III/IV and V/VI bladder outlet obstruction (mean 11.285 ± 4.069 vs 11.781 ± 4.437 pg/μmol, p = 0.354). However, differences were significant for urinary nerve growth factor/creatinine levels in patients without overactive bladder, and mild, moderate and severe overactive bladder (mean 8.132 ± 3.489, 10.128 ± 3.817, 13.232 ± 3.290 and 14.029 ± 3.820 pg/μmol, respectively, p <0.001). One year after transurethral prostate resection we noted a decrease vs baseline in mean urinary nerve growth factor/creatinine (8.978 ± 4.022 pg/μmol, p <0.001), and I-PSS and OABSS (10.2 ± 5.4 and 4.3 ± 3.7, respectively, each p <0.001). Compared with the good outcome group, the fair/poor group had higher mean baseline urinary nerve growth factor/creatinine (12.319 ± 4.017 vs 11.015 ± 4.298 pg/μmol, p = 0.045), higher mean 1-year urinary nerve growth factor/creatinine (10.847 ± 4.267 vs 7.850 ± 3.419 pg/μmol, p <0.001) and a lesser mean postoperative change in urinary nerve growth factor/creatinine (1.472 ± 4.928 vs 3.165 ± 4.863 pg/μmol, p = 0.031). CONCLUSIONS: Nerve growth factor was associated with overactive bladder symptoms in patients with benign prostatic hyperplasia as well as with the assessment of successful long-term treatment outcome of bladder outlet obstruction with symptoms of overactive bladder.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Hu H, Zhang W, Liu X, et al. Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia. J Urol. 2018. PMID: 29630981. doi:10.1016/j.juro.2018.03.130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。